Download Mendelian Traits

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Epigenetics of neurodegenerative diseases wikipedia , lookup

Fetal origins hypothesis wikipedia , lookup

Gene expression programming wikipedia , lookup

Genetic engineering wikipedia , lookup

Twin study wikipedia , lookup

Metabolic network modelling wikipedia , lookup

Gene therapy wikipedia , lookup

Hardy–Weinberg principle wikipedia , lookup

Epistasis wikipedia , lookup

Nutriepigenomics wikipedia , lookup

Gene wikipedia , lookup

Site-specific recombinase technology wikipedia , lookup

Behavioural genetics wikipedia , lookup

Artificial gene synthesis wikipedia , lookup

X-inactivation wikipedia , lookup

Gene therapy of the human retina wikipedia , lookup

Genetic drift wikipedia , lookup

Vectors in gene therapy wikipedia , lookup

Public health genomics wikipedia , lookup

Neuronal ceroid lipofuscinosis wikipedia , lookup

Point mutation wikipedia , lookup

Population genetics wikipedia , lookup

Quantitative trait locus wikipedia , lookup

NEDD9 wikipedia , lookup

Microevolution wikipedia , lookup

Genome (book) wikipedia , lookup

Designer baby wikipedia , lookup

Dominance (genetics) wikipedia , lookup

Medical genetics wikipedia , lookup

Transcript
Chapter 7
Mendelian Traits
This chapter describes several “Mendelian” traits that have relevance to human
behavior. A Mendelian trait or disorder is one that is due to a single gene
and not to the effects of a large number of genes. The purpose is to reinforce
learning and to illustrate several new concepts about how a gene can relate to
behavior.(Zucker et al., 1996a)
7.1
Terminology
Let us now examine three central terms that describe the relationship between
a single gene and a phenotype. The first of these is penetrance of a genotype.
Penetrance is defined as the probability that a person exhibits a phenotype given
that the person has the genotype for that phenotype. When applied to disease–
as the term usually is–penetrance refers to the probability that a person will
develop the disorder given that the person has the genotype for the disorder.
Penetrance is a conditional probability, so it is literally a number that can
logically range from 0 to 1.0. Complete penetrance refers to disorders and traits
where the probability is very close to 1.0. Thus, if a person has the genotype,
s/he will almost always develop the disorder. Huntington’s disease and cystic
fibrosis are two examples of disorders with complete penetrance. Incomplete
penetrance occurs when the probability is significantly less than 1.0. Marfan’s
syndrome is a classic example of a disorder with incomplete penetrance. About
half of the people with the gene for Marfan’s syndrome actually develop the full
syndrome.
The second phenomenon relating genotype to phenotype is pleiotropism or
pleiotropy. Pleiotropy refers to the phenomenon that a single gene can influence
more than a single phenotype. For example, the Huntington’s disease gene can
influence several different phenotypes. Two phenotypes—intellect and movement—will be used here to demonstrate pleiotropism. Huntington’s disease
(HD) usually has an onset in midlife around age 40 and is initially noticed by
increasing clumsiness. As the disorder progresses, the person gradually develops
1
7.2. PHENYLKETONURIA
CHAPTER 7. MENDELIAN TRAITS
involuntary motor movements in the head and limbs . The loss of voluntary motor control worsens and the person eventually loses the ability to walk and feed
himself. Even before these motoric problems are noticeable enough to diagnose
HD, there is often a decline in intellectual functioning that is imperceptible to
the person or his family. As HD progresses, the decline accelerates and becomes
noticeable. Eventually dementia (the progressive and irreversible loss of cognitive functioning) occurs. Hence, one aspect of pleiotropy for the HD gene is its
influence on both cognitive processes as well as motoric behavior.
The third phenomenon relating genotype to phenotype is variable expressivity. Variable expressivity applies to a continuous or quantitative trait, i.e, a trait
that everyone possesses but has different amounts of it. Height is an example.
Variable expressivity occurs when a single gene results in a range of phenotypic
values for a single trait. A classic example is the relationship between intelligence and phenylketonuria (PKU). When untreated, PKU reduces the average
cognitive ability of affected individuals. However, PKU exhibits variable expressivity because it results in a significant range of IQ scores. Some children with
untreated PKU are severely mentally retarded while other untreated children are
in the low, normal range of IQ. As you read about Mendelian traits and disorders
in the following pages, keep in mind these three basic phenomenon—penetrance,
pleiotropy, and variable expressivity.
7.2
Phenylketonuria
Phenylketonuria or PKU is the poster child for behavioral genetics because
an effective environmental intervention can ameliorate the damaging effects of
the disorder. Clinically, untreated PKU babies are physically normal at birth
but develop symptoms within the first year of life. These symptoms include
mousy smelling urine and sweat; small head size (microcephaly); motoric abnormalities in posture, stance, and gait; light colored skin, blond hair, and blue
eyes (hypopigmentation); eczema; seizures; intellectual deficiency; irritability;
and hyperactivity. There are several lessons that PKU teaches us about genes.
They are a metabolic block, therapeutics for a genetic disorder, pleiotropism, and
allelic heterogeneity. We discuss each in turn.
7.2.1
Metabolic block
PKU is a recessive disorder—the disorder is expressed only when two deleterious
alleles come together in the same individual. People who inherit one normal allele and one deleterious allele are phenotypically normal but are often referred to
as carriers. A recessive mode of inheritance is common for disorders involving
metabolic enzymes. As a general rule, the mRNA transcripts and the translated enzymes from only one DNA segment (i.e., allele) is sufficient to maintain
metabolism.
The genetic defect underlying PKU is an abnormality in the enzyme phenylalanine hydroxylase (PAH), the gene for which is located on the long (i.e., q)
2
CHAPTER 7. MENDELIAN TRAITS
7.2. PHENYLKETONURIA
Figure 7.1: Metabolic pathways for phenylketonuria and other metabolic blocks.
3
7.2. PHENYLKETONURIA
CHAPTER 7. MENDELIAN TRAITS
arm of chromosome 12. Part of the metabolic pathway that involves this enzyme
is depicted in 7.1. Let us spend some time going through this figure so that we
can learn about the pathways from gene to behavior. The relevant portion of
the figure is the upper, left quadrant.
Phenylalanine is an amino acid and, hence, a necessary constituent of peptides, proteins, and enzymes. The two major sources of phenylalanine are diet
and the breakdown of cellular proteins and enzymes into their basic amino acids;
hence arrows are drawn from diet and tissue proteins into phenylalanine in the
figure. Three things occur to the phenylalanine in our system: (1) it is used to
build peptide chains, depicted in the figure by the arrow from phenylalanine to
tissue proteins; (2) it acts as a substrate for the construction of another amino
acid, tyrosine; and (3) it is degraded into phenylpyruvic acid and other phenyl
derivatives. The enzyme PAH is responsible for the second of these—the conversion of phenylalanine into tyrosine. When PAH is defective, then it acts as a
metabolic block. The term metabolic block is very important in genetics because
it describes the mechanism for a large number of Mendelian disorders. Generally, it refers to a defective enzyme that results in the build up of precursor
substances in a metabolic pathway. In PKU, phenylalanine and phenylpyruvic
acid build up in the body and the amount of tyrosine is reduced. By some
unknown mechanism, damage occurs to the nervous system, leading to mental
retardation and some of the neurological symptoms noted above.
Figure 7.1 also illustrates a series of other metabolic blocks that occur in
the pathways of tyrosine metabolism. For example, a block in the conversion
of tyrosine to thyroxine results in a syndrome called goitrous cretinism and a
block in the conversion of DOPA to melanin results in a form of albinism. It
is not necessary to know these syndromes. The important point is that there
are many metabolic blocks that lead to phenotypic irregularities and medical
disorders.
7.2.2
Therapeutics: Diet
At this stage, let us postpone discussion of the metabolic pathway to focus
on the second major lesson from PKU—an effective environmental therapy.
Because something associated with excess phenylalanine is responsible for PKU
and because diet is a major source of phenylalanine, restricting the dietary intake
of phenylalanine sounds as if it might prevent the harmful symptoms of PKU.
Indeed, this is the case. Currently all newborns in modern industrialized nations
are pricked on a heel and the small quantity of blood is tested for excessive levels
of phenylalanine and phenylpyruvic acid. If this test is positive, a more sensitive
test is performed to confirm the diagnosis. The parents are informed, and the
infant is placed on a special formula. The infant cannot have mother’s milk, cow
milk, or standard formula, and after weaning, must avoid all foods with high
levels of protein and be maintained on special dietary supplements. In typical
medical practice, the diet is individualized. Blood levels of phenylalanine are
constantly monitored and the diet adjusted to keep the levels within safe limits.
Many PKU children will eventually be able to tolerate certain fruits, vegetables,
4
CHAPTER 7. MENDELIAN TRAITS
7.2. PHENYLKETONURIA
and grains that are low in phenylalanine. The biggest limiting factor is the
child’s adherence to the dietary recommendations.
If the diet is adhered to, then the mean IQ of children with PKU does not differ markedly from normals. They do, however, show a number of minor deficits
in cognition and psychological functioning. Many finer issues about the diet are
still debated—e.g., the levels of blood phenylalanine that are considered safe
(Diamond, 1994; Trefz et al., 2011); the age at which the diet may be discontinued, if indeed it can be discontinued at all Azen et al. (1996); Burgard et al.
(1996); Griffiths et al. (1995); Trefz et al. (2011); and the importance of supplementing the diet with tyrosine (Diamond, 1996). There is an active research
agenda into predicting when and for whom the diet may be safely discontinued.
Despite such uncertainties, PKU is a clear indication that a genetic influence
on a disorder is no cause for therapeutic nihilism. Even if something is 100%
genetic, the environment may still present an effective way of dealing with it.
7.2.3
Pleiotropism
We can now return to the metabolic pathway. Because the enzyme PAH is
damaged, the amount of tyrosine is reduced in PKU. Tyrosine itself is converted
to DOPA which, in skin cells, eventually produces pigment (melanin). The
reduction in tyrosine and hence, pigment, is apparently the reason why the
skin, hair, and eye color of individuals with PKU is lighter than that of their
normal sibs.
Tyrosine also acts as a precursor to DOPA which is eventually synthesized into the neurotransmitters dopamine and norepinephrine. It is possible—although not really known—that the some behavioral consequences of PKU
may be associated with deficits in these neurotransmitters, especially dopamine
(Diamond, 1996).
We have now encountered the second major lesson that PKU has for the
genetics of behavior—pleiotropism or the phenomenon of a single gene influencing more than one phenotype. The PAH locus, for example, effects anatomy
(small head size and undermylenization of the nerve cells) and physiology (reduced melanin production) as well as several domains of behavior—cognition,
personality, and motor functioning. Pleiotropism is far from rare among genetic
disorders. Indeed, the eminent geneticist Sewall Wright stated that all genes
are pleiotropic.
A moment’s reflection on the metabolic pathway in 7.1 gives a convincing
illustration of Wright’s concept of universal pleiotropism. The biochemical systems mediated by enzymes and receptors (and thus by the genes that code for
these enzymes and receptors) are highly interconnected with feedback loops and
other regulatory mechanisms to insure that the system does not capriciously shut
down or turn into a runaway process that damages the organism. If a monkey
wrench is thrown into such an interdependent system—just like the defective
PAH enzyme is thrown into the metabolic pathway in Figure 7.1—then there
will be a large number of consequences both upstream and downstream from
the point that the monkey wrench does its damage. With this in mind, it would
5
7.2. PHENYLKETONURIA
CHAPTER 7. MENDELIAN TRAITS
actually be very surprising to find that a major defect in a single gene would
influence one and only one phenotype.
Our previous consideration of evolutionary principles is also consistent with
universal pleiotropism. Evolution is a pragmatic tinkerer with no forethought
beyond fixing something so that organisms can reproduce at an acceptable rate.
Hence, it is likely to alter something that already exists in an organism’s biochemistry rather than design a system de novo to solve a reproductive problem.
If an organism with pigment needs a specialized neurotransmitter, then evolution is more likely to tinker with the enzymes that act on tyrosine to let it
eventually produce dopamine than start out with a brand new substrate and
construct a novel metabolic path for it. Hence, it is not unreasonable for the
evolutionist to find that the production of skin pigment has something to do
with neurotransmission even though there is no logical connection between the
two.
7.2.4
Allelic heterogeneity
Like most Mendelian disorder, PKU exhibits the phenomenon of allelic heterogeneity—the fact that many different alleles at a single locus can produce the
same syndrome. Again, this is a logical consequence of what we have learned
about the biological nature of the gene. There are many ways in which the DNA
blueprint for the PAH enzyme can go awry and if any one of them happens, then
the translated product of that DNA will not work correctly. As a result, over
500 different alleles at the PAH locus can cause the disorder (Scriver et al.,
2003). If any two of these hundred or so alleles come together, then some form
of PKU will result. Because there are so many different alleles, few people with
PKU have the same nucleotide sequence at both of their PAH genes.
Allelic heterogeneity may be responsible for some of the variable expressivity
in the disorder. Some alleles will result in no functional PAH. If someone inherits
two of these, then the clinical manifestation will likely be severe. Other alleles
may produce PAH enzyme but its functionality is impaired. Someone inheriting
two alleles within this category may have milder manifestations. Again, there
is an active research examining the correlation between the genotype and the
phenotypic consequences from this allelic variation (Cleary et al., 2013; Koch
et al., 2003b; Trefz et al., 1993b). Paradoxically, however, treatment success
has, mercifully, impeded this research. As Mitchell et al. (2011) point out, “It is
becoming more difficult to assess clinical phenotypes given that most individuals
with PAH deficiency in developed countries are treated successfully.”
While allelic heterogeneity may explain some of variability in the clinical
manifestations of PKU, it cannot explain all of it. DiSilvestre et al. (1991),
for example, presented the intriguing case of three siblings all of whom had the
same genes for PKU yet differed significantly in their clinical pictures.
A final lesson from PKU comes from examining the IQ distribution in untreated cases. Here, we must go back several generations to examine the relevant
data because virtually all PKU cases in modern industrialized countries are now
detected and treated at birth. Hence, untreated cases are rare.
6
CHAPTER 7. MENDELIAN TRAITS
7.3. FRAGILE X SYNDROME
When definitive tests for PKU were first developed, it was noted that some
siblings of a PKU individual tested positive for PKU but did not suffer from
severe mental retardation. Although few had IQ above the average in the general
population, a significant number fell into the low normal range. Why? The
reason for this is a mystery and is likely to remain a mystery for some time—it
would be unethical and cruel to withhold the dietary intervention in order to
identify those whose eventual IQs fall into the normal range. Still, this fact
underscores the variable expressivity that can occur with PKU and IQ.
7.3
Fragile X syndrome
The fragile X syndrome (FXS) was first described by Martin and Bell (1943) although it took several decades to fully characterize the disorder. Initially called
the Martin-Bell syndrome, its current name comes from karyotypes in which it
appeared that a section of the X chromosome was close to breaking off from the
main body. It is the the most common Mendelian disorder among folks with
intellectual deficiency (ID, formally known as mental retardation). It is also
the most common single gene disorder associated with autism and autism spectrum psychopathology (Budimirovic and Kaufmann, 2011; Wang et al., 2012).
Despite this, FXS is not common in an absolute sense. Its prevalence is approximately 1 in 4,000 births in males and and 1 in 8,000 births in females, although
like most Mendelian traits, there are wide differences in prevalence as a function
of ethnicity (Peprah, 2012).
Several physical features are associated with FXS. These include flat feet, an
elongated face with prominent forehead, jaw and ears, and in males, enlarged
testicles (AKA macroorchidism) after puberty. These phenotypes are subtle
mean differences from the average trait in normals, so it is not possible to
diagnose the syndrome from them.trinucleotide
The most common medical correlates are neurological. They include seizures
which often develop during childhood, problems in vision, and poor motor coordination. Later in life, those with FXS are at risk for developing a progressive
neurological disorder characterized by tremor, ataxia (incoordination of voluntary movements) and dementia.
Rarely diagnosed at birth, most cases come to medical attention because of
behavioral problems and irregularities during early development. These include
delayed speech and language, hyperactive and impulsive behavior and problems
in social interactions, especially poor eye contact. Not all children with FXS,
however, demonstrate such symptoms. It is not unusual to discover a FXS child
who is adapting well at home and at school but is diagnosed only because a
younger sibling exhibits a more virulent form of the disorder. Hence, there is
marked variable expressivity for behavioral phenotypes in this disorder.
This variable expressivity makes it difficult to arrive at precise prevalence estimates and figures about the syndrome’s association with ID and psychopathology. Only those cases with problems (and their affected relatives) come to the
attention of doctors and researchers. We do not know the number of FXS in the
7
7.3. FRAGILE X SYNDROME
CHAPTER 7. MENDELIAN TRAITS
Figure 7.2: Schematic of the relationship between the trinucleotide expansion
and the amount of FMR1 protein (FMRP) in Fragile X syndrome. (The arrow
is conventional notation for a gene denoting the direction of transcription.)
general population that do not come to medical attention because their behavior
is within normal limits.
The gene responsible for FXS is located on the X chromosome (Xq27.3) and
is called FMR1 (for fragile mental retardation 1). It codes for a protein called
FMRP (fragile mental retardation protein) that is found in many tissues but
especially in neurons. Not all of the many functions of FMRP are known, but
it binds to RNA and together with other factors, inhibits translation. It is also
associated with the transport of mRNA through the cytoplasm to the dendrites
and synaptic buttons of the neuron Santoro et al. 2012. When the amount of
FMRP is low, translation of some proteins is not inhibited, particularly in the
dendrites. This may lead to the formation of an excess number of dendrites
which is known to be associated with neurological problems.
The clinical severity of FXS is directly correlated with the amount of FMRP–
the lower the amount of FMRP, the greater the severity Hagerman and Hagerman 2002 . The most severely affected individuals are those with no detectable
FMRP.
The reason behind the pathology is an abnormal number of trinucleotide
repeats (nucleotides CGG) in an untranslated region of the gene close to a promoter (see Figure 7.2). All humans have a series of CGG repeats in this area,
but in normals the number of repeats ranges from 6 to 44. Alleles in this range
are called common. Alleles with repeats between 45 and 54 fall into a gray zone
and are termed intermediate (Seltzer et al., 2012). Once the number of repeats
exceeds 54, the allele is called a premutation because it is hypermutable (susceptible to mutations that further expand it). People with a permutation are called
carriers. 1 When a mutation expands it to 200 repeats or greater, the region
1 The
cutoffs among common, intermediate and premutation alleles are a matter of debate.
8
CHAPTER 7. MENDELIAN TRAITS
7.3. FRAGILE X SYNDROME
becomes abnormally methylated and transcription is inhibited, sometimes to
the point of completely silencing the gene. This is termed a “full mutation.”
The numbers separating common, intermediate, premutation and full mutation alleles should be regarded as “fuzzy” thresholds. Those with a premutation,
for example, may still show some signs of FXS, particularly ataxia, later in life
(Peprah, 2012; Turk, 2011). Similarly, the number of repeats within a premutation allele is correlated with the probability that it will mutate past the the
threshold into a full mutation (Mandel and Biancalana, 2004). For this reason,
not all researchers use the same cut offs for the various categories.
In males, there is almost 100% penetrance in the sense that all show some
symptoms, however, mild. Because of variable expressivity, however, the mildness of the symptoms may result in minimal impairment. Because of the rarity
of an X chromosome with a full mutation, almost all affected females are heterozygotes. In females, however, the syndrome exhibits partial or incomplete
penetrance with a wide range of severity in symptoms. On average, however,
the symptoms in females are less severe than those in males.
7.3.1
Trinucleotide repeats
Unstable and expanding trinucleotide repeats are a mechanism for several neurological disorders, not merely for Fragile X. They cause Huntington’s disease,
some forms of muscular dystrophy and some dementing illnesses involving the
fontal and temporal areas of the brain (Nelson et al., 2013). In FXS, the mechanism is abnormal methylation which reduces transcription of a gene whose
product is necessary to limit translation of certain proteins. In almost all of the
other disorders, the mechanism is different.
While the trinucleotide in FXS is CGG, it is CAG in the other disorders and the
repeat occurs in a coding exon of the gene. The CAG codon codes for glutamine,
so the result is a long string of glutamine amino acids somewhere in the protein.
From there, these polyglutamaine disorders remain mysterious with many more
questions than answers. Why are individuals asymptomatic at birth and early
childhood but become affected mostly during the middle adult years? Why does
pathology involve three nucleotides and not two or four?
The discovery of the trinucleotide repeat association with pathology has
prompted considerable research into trinucleotide repeats and psychiatric disorders. To date, no firm associates have been reported.
7.3.2
Anticipation
Anticipation is the phenomenon in which the age of onset decreases and/or
severity of a disorder increases in more recent generations of a pedigree. This
was a controversial topic in genetics, but work on Fragile X and other trinucleotide repeat disorders confirmed it as a phenomenon. The story begins
with Stephanie Sherman’s analysis of pedigrees with Fragile X (Sherman et al.,
See Seltzer et al. (2012).
9
7.3. FRAGILE X SYNDROME
CHAPTER 7. MENDELIAN TRAITS
1985b, 1984b). She and her colleagues noticed several instances in which the
disorder was transmitted by an unaffected male. In ordinary genetics, both the
mothers and the daughters of these male carrier should have the gene with equal
frequency. Hence, the severity of FXS in the male carrier’s siblings should be
the same as that in the male carrier’s grandchildren. But they were not. The
severity in the male carrier’s grandchildren was greater than that in his siblings.
The reason for this paradox is the hypermutability of trinucleotide expansions. As one moves down the pedigree from ancestral generations to the current
one, the length of the expansion increases. Hence, affected individuals in recent
generations have longer expansions than those in distant generations. The result is often a decrease in age of onset for disorders like Huntington’s disease
and an increase in severity for FXS as one moves down the pedigree.
7.3.3
Variable expressivity
Perhaps the most striking feature of Fragile X syndrome is its variable expressivity. Individuals with the full mutation (i.e., more than 200 CGG repeats) can
have social behavior than ranges anywhere between social hyperexuberance and
abnormal overdetachment. Although mean IQ is somewhere between 60 and 70,
the standard deviation of IQ scores is not remarkably different from that in the
normal population. Hence, some Fragile X individuals are within the low-normal
limits and can profit from standard public education while others require special interventions for their cognitive impairment and learning problems. Some
cases may exhibit socially engaging behavior; others may be characterized by
inappropriate aggression.
7.3 presents a hypothetical pedigree that illustrates both anticipation and
the variable expressivity of the Fragile X phenotype. The progenitor is the X
chromosome carried by the male parent at the top of the pedigree. This chromosome has 29 CGG repeats, so he is normal. It is passed along intact to the first
daughter. But in the genesis of the sperm that results in the second daughter, a
mutation occurs that expands the CGG sequence from 29 to 125 repeats. The
number of repeats in this daughter is now within the 50 to 200 range which
means that the FMR-1 locus on this chromosome is now “hypermutable,” or at
a very high risk of mutating to longer CGG repeats in future generations.
Because the X chromosome for this woman has 125 CGG repeats (and also
because her other chromosome has a normal number of repeats), she is unaffected. However, when she generates her eggs, they have an increased probability
of mutating to a longer series of repeats. (Actually, hypermutability is much
more common in sperm than in eggs, so this woman is the exception rather than
the rule.) A mutation occurs in one of her eggs and a sequence of 246 CGG
repeats is passed to her firstborn, a daughter. This passes the critical level of
200 repeats, so this daughter may show mild signs of the syndrome but would
probably be well within the normal range of behavior because she is “buffered”
or protected by the good FMR-1 locus on her other X chromosome. For example, she may have an IQ that is lower than that predicted by her family history
and she may show minor difficulties with attention, but these symptoms may
10
CHAPTER 7. MENDELIAN TRAITS
7.3. FRAGILE X SYNDROME
Figure 7.3: A pedigree illustrating anticipation.
11
7.4. CONGENITAL ADRENAL HYPERPLASIA
CHAPTER 7.
(CAH)
MENDELIAN TRAITS
not be noticeable enough to have her referred to a school psychologist.
The mutation also occurs in the X chromosome transmitted to her brother,
who receives 288 CGG repeats. The difference between these 288 CGG repeats
and the 246 repeats in his sister is relatively minor, but because the male lacks
an extra X chromosome, he is not protected from its deleterious effects. He is
likely to show features of the Fragile X phenotype, although they will be on
the less severe side. For example, he may have learning difficulties at school,
be diagnosed with mild intellectual deficiency, and exhibit enough attention
problems and hyperactivity to qualify for a possible or probable diagnosis of
ADHD.
His sister marries and has two children, both boys. The hypermutability
of the locus is evident in the number of CGG repeats inherited by both of her
sons. The first inherits a FMR-1 locus with 749 repeats. He is likely to show a
full-blown syndrome with some irregularity in facial features, moderate mental
retardation, marked attention difficulties, and other behavioral problems. He
may be placed in a special education program for the developmentally disabled
and also be given medication for ADHD. By bad luck, his brother also inherits
the hypermutable X chromosome but the repeats in his case number 1036. He
shows severe Fragile X. In addition to mental retardation, he could have the
physical irregularities of facial appearance that make him appear “unusual” in
a very amorphous and inarticulable sense to casual observers. He could have
serious learning disabilities and problems with attention and concentration. In
addition, his social behavior may be awkward enough that some psychologists
might consider him as having autistic features.
7.4
Congenital adrenal hyperplasia (CAH)
Congenital adrenal hyperplasia (CAH) is a medical syndrome that illustrates
genetic heterogeneity. In genetic heterogeneity, the same syndrome (or very
similar syndromes) can appear from defects (or differences) at more than a single
locus. A defect in any one of the loci can produce the syndrome. Albinism is
another example of a genetically heterogeneous syndrome.
In CAH, there is a metabolic block somewhere in the synthesis of cortisol
from cholesterol in the adrenal gland. 7.4 illustrates the metabolic pathway.
There are five different steps in cortisol synthesis, and if any one of these steps
is blocked then some form of CAH can result. There is a reduction of cortisol
and a build of the precursors to cortisol synthesis. Like most metabolic blocks,
the genes for CAH are recessive. That is, to exhibit the syndrome, one must
have two defective alleles at a single locus.
The five forms of CAH have different prevalences. Over 90% of cases arise
from the deficiency in the enzyme 21-hydroxylase. Note also the variability in
medical outcomes. Four of the forms can be managed medically but 3-b-OHdehydrogenase deficiency remains lethal.
Having established that CAH is genetically heterogeneous, let us focus on
the most common form of CAH, 21-hydroxylase deficiency. Because this is
12
CHAPTER 7. MENDELIAN
7.4. CONGENITAL
TRAITS ADRENAL HYPERPLASIA (CAH)
an autosomal recessive disorder, it will occur in XY and XX individuals with
equal frequency. XY individuals have normal external genitalia but often have
problems such as high blood pressure (hypertension) and salt loss that require
medical intervention.
The situation is quite different in
the fetus who is chromosomally XX.
Re-examine Figure 7.4. With the Figure 7.4: Metabolism of cortisol and
metabolic block, there is a build up metabolic blocks that can lead to a
of the precursor 17-hydroxy pregne- form of congenital adrenal hyperplasia;
nalone which also acts as a precur- included are the form of the genitalia
sor to the synthesis of various andro- in affected females (red), androgen levgens (masculinizing hormones). In els (green), and medical complications
the XX fetus, initial sex develop- (blue).
ment proceeds normally, so the tissues develop into the usual internal
sex organs—ovaries, fallopian tubes,
etc. The high dose of male hormones,
however, occurs at the time in embryogenesis when the external genitalia develop. This will change the development of these tissues away from
the clitoris and labia and toward a
penis and scrotum. The extent of
virilization (i.e., masculinization) of
external genitalia is variable. Differences can range from clitoral enlargement through ambiguous genitalia to genitalia that so closely resemble a male that they go unrecognized at birth. The typical medical
intervention for the virilized girls is
to surgically correct the genitalia to
agree with chromosomal sex. They
are then raised as girls.The intriguing
feature of virilization for the study of
behavior is the effect of the early dose
of androgens on brain development.
Prenatal androgens have been shown
to influence early rough and tumble
play, aggression, and copulatory behavior in both rodents and primates.
Could the same be true of humans?
Sheri Berenbaum and her colleagues have begun systematic research into
children with CAH. In one study, Berenbaum and Hines (1992b) her group
tested CAH boys and girls and their unaffected siblings in a toy preference situation. The experimental paradigm, used extensively in past research on child
13
7.4. CONGENITAL ADRENAL HYPERPLASIA
CHAPTER 7.
(CAH)
MENDELIAN TRAITS
development, involves placing a child into a room with toys that are stereotypically “boyish” (e.g., a fire engine), stereotypically “girlish” (e.g., dolls) or neutral
(e.g., a book). The child can freely play with any toy(s) that s/he chooses while
an assistant records the toys that are played with and the amount of time played
with each toy.
There is considerable individual variability in children in which toys they
play with, but on average boys spend more time with the trucks while girls
spend more time on the dolls. The control boys and girls in this study showed
exactly this play pattern. The CAH boys were no different than the control
boys. Indeed, there are no differences between CAH boys and control boys
on a wide of sex-stereotypical behavior. This suggests that the extra prenatal
androgen does not “super masculinize” a boy.
The CAH girls, on the other hand, exhibited a preference that resembled
the control boys more than the control girls. Berenbaum and Hines were unable
to find that parental treatment or degree of childhood illness could account for
this and suggest that the masculinization of phenotypic toy preferences in these
girls may have been due to the prenatal effects of androgens.
Other research suggests that CAH girls differ from their unaffected sisters
(or appropriate controls) in a more masculine direction. They show more aggression (Berenbaum and Resnick, 1997b) or at least more masculinized forms
of aggression (Helleday et al., 1993b), and more masculine-related social behavior and activity levels (Dittmann et al., 1990c,b). They express less interest in
infants an in maternal behavior have have lower empathy than controls (CohenBendahan et al., 2005a). Cognitively they score higher than unaffected girls on
spatial visualization and spatial orientation, two variables with an established
sex difference (Berenbaum et al., 2012; Cohen-Bendahan et al., 2005a). Finally,
they also have a higher frequency of same-sex orientation than their female peers
(Cohen-Bendahan et al., 2005b; Dittmann et al., 1992a; Zucker et al., 1996a).
However, CAH girls are far from being boys in girls’ bodies. In all of the
phenotypes, CAH girls have means between control girls (or women) and males.
For example, over 70% of CAH women have a heterosexual orientation.
One of the most intriguing facts to emerge from the CAH literature is that
the largest difference between the CAH girls and unaffected controls is on interest patterns (Cohen-Bendahan et al., 2005a). Most psychologists had thought
that interests would be highly malleable since there have been marked secular
trends over the 20th century in women’s vocational aspirations in, say, medicine
and law. Why interest patterns differ more than personality traits like aggression or cognitive traits like spatial visualization remains an intriguing mystery.
CAH illustrates how a Mendelian trait can be used as a quasi-experiment
to examine hormonal influences on behavior. Like all work on substantive human behaviors, the CAH story is not a clean and neat laboratory experiment
and there are important confounding factors. Virilized girls undergo surgery
and many also have hormone replacement therapy to counter the effects of low
cortisol levels. Still the data on virilized CAH girls agree with the experimental
manipulation of prenatal hormones in birds, rodents, and primates. There appears to be a sensitive period during which hormones exert an influence on later
14
CHAPTER 7. MENDELIAN
7.5. ALDEHYDE
TRAITS DEHYDROGENASE-2 DEFICIENCY
Figure 7.5: Metabolic pathway for alcohol metabolism.
sex-typed behaviors. How prenatal hormones do this work is a topic of intense
research.
7.5
Aldehyde Dehydrogenase-2 deficiency
After alcohol is ingested, it enters the stomach and small intestine where it is
absorbed into the bloodstream and carried throughout the body. The major
organ that metabolizes alcohol is the liver. Here, alcohol is converted into
acetaldehyde by the enzyme alcohol dehydrogenase (ADH), and acetaldehyde is
then converted into acetic acid by the enzyme aldehyde dehydrogenase or ALDH
(see Figure 7.5). There are several genes that have blueprints for ALDH, each
of which makes different forms of this enzyme in different tissues of the body.
One gene, ALDH2, codes for the major form of this enzyme located in liver
mitochondria where most ingested alcohol is metabolized.
When a person has ALDH-2 deficiency, then the acetaldehyde cannot be
readily converted into acetic acid and acetaldehyde builds up in the system.
The amount of build up depends, of course, on the amount of alcohol ingested
and the time course of ingestion. When the build up of acetaldehyde is rapid, the
person may show the symptoms of a “flushing” response in which the person’s
face turns red. (The reason is peripheral vasodilation. The blood vessels in the
periphery become enlarged and carry more red blood).
In addition to flushing, excess acetaldehyde may cause some unpleasant effects, notably dizziness and nausea. Disulfram (Antabuse®) produces a similar
reaction because it inhibits the ALDH enzyme.
Many individuals with ALDH2 deficiency develop mild conditioned food
aversions to alcohol while others reduce the amount of drinking to avoid the
unpleasant symptoms. Because these individuals abstain or are temperate
drinkers, the risk for developing alcohol abuse and alcohol dependence is reduced. Consequently, when individuals with this allele drink alcohol, the pathway from acetaldehyde to acetic acid is blocked (or greatly diminished in activity), and acetaldehyde accumulates in the blood and tissue.
Both the ALDH2 allele and the flushing response are associated with alcohol metabolism and elimination (Steinmetz et al., 1997; Yin, 1994), drinking
habits (Higuchi et al., 1996; Nakawatase et al., 1993; Muramatsu et al., 1995;
Tu and Israel, 1995), alcoholism (Murayama et al., 1998; Thomasson et al.,
1991; Yoshida, 1992), and alcoholic liver diseases (Tanaka et al., 1997; Yoshida,
1992). Individuals with this allele are more often abstainers or, those who do
15
7.5. ALDEHYDE DEHYDROGENASE-2
CHAPTER
DEFICIENCY
7. MENDELIAN TRAITS
drink imbibe lower quantities of alcohol and engage in less binge drinking than
those without the allele (Tu and Israel, 1995). Thus, the allele appears to lower
the risk for the development of alcohol-related problems.
As many as 50% of Orientals posses an allele at the ALDH2 locus that
results in an ALDH2 enzyme molecule that has either greatly reduced activity
or no activity at all (Goedde et al., 1983; Yoshida, 1992). Because the allele is
present among different Asian populations, but is either missing or extremely
rare among Caucasoids and Africans, it has been postulated as one of the factors
that contribute to lower rates of drinking among Asians. Tu and Israel (1995)
go so far as to claim that this gene is the major predictor of the difference in
drinking habits between Asians and other ethnic groups in North America. The
reason why the allele for ALDH2 deficiency is so high in some Asian groups is
not understood.
The ALDH-2 polymorphism is a classic example of how a gene can influence behavior. The mechanism of its action can be traced all the way from the
DNA to the substantive behavior. First, at the DNA level, a single nucleotide
(an adenine replaces a guanine) substitution at the ALDH-2 locus results in
an altered polypeptide chain in which lysine replaces the usual amino acid glutamate. To get the enzyme molecule, four of these polypeptide chains must
be joined together. If a person is homozygous for the deficient allele, then all
four polypeptide chains have the deficiency and the person has virtually no viable ALDH2 enzyme. These homozygotes can become alcoholic but at vastly
reduced rates. Chen et al. (1999) report that they are 100 fold less likely to
develop alcohol dependence than someone with two normal alleles.
For a heterozygote–one normal allele and one deficient allele–the only active
ALDH enzyme molecules in the liver will occur when, by dumb luck, all four of
the peptide chains from the good allele get joined together. The probability of
this occurring is 1/16, so only 6% of the ALDH2 molecules in the heterozygote’s
liver are capable of fully converting acetaldehyde to acetic acid. This is the likely
reason why ALDH-2 deficiency shows some degree of dominance.
There are also other very important lessons from the ALDH-2 story. First,
it has been repeatedly demonstrated that people with the deficiency can still
become alcoholic. For example, Thomasson et al. (1991) report that 12% of
Chinese alcoholics in Taipei were heterozygotes for this gene. Thus, the gene
influences risk, but in the heterozygote, it does not guarantee a life free of alcohol
problems. Many geneticists refer to this type of a locus as a major susceptibility
gene or a major locus—depending upon background genotype and environmental factors, it increases or decreases the probability of alcohol problems but does
not rigidly determine alcohol use.
Second, the enzyme defect does its work in the liver, not in the central
nervous system. There is a natural tendency to suspect that genetic effects
on behavior operate on development of the nervous system and on the enzymes
and proteins responsible for communication among neurons. The ALDH-2 story
is a sober reminder that genes operating elsewhere in the body can influence
behavior. Could some forms of schizophrenia turn out to be liver disorders?
16
CHAPTER 7. MENDELIAN TRAITS
7.6. SICKLE CELL DISEASE
Figure 7.6: A sickled red blood cell among several normal, platelet-shaped red
blood cells.
From:
http://www.nature.com/scitable/topicpage/
sickle-cell-anemia-a-look-at-global-8756219
7.6
Sickle cell disease
Sickle cell disease (SCD, aka sickle cell anemia) is a recessive disorder due to
alleles that influence the b chain of the hemoglobin molecule. The sickle cell
anemia allele is a point mutation (i.e., the substitution of just one nucleotide
for another) that results in a different amino acid being substituted into the b
polypeptide2 .
The effect of this amino acid substitution is profound. After the hemoglobin
molecule transfers the oxygen to the target organ, the hemoglobin molecules
often line up in a side to side fashion to create a long thin string. The abnormal
hemoglobin from the sickle cell allele causes these strings to form into rigid
bundles that change the shape of the red blood cell from a platelet into an
elongated form (Mirchev and Ferrone, 1997). Viewed under the microscope, the
elongated red blood cells often resemble the blade of a sickle, giving the disorder
its name See Figure 7.6).
The altered shape of the red blood cells has two major consequences. First it
makes it easier for them to be destroyed, contributing to anemia (low red blood
cell count). Second, the sickled shape makes it much easier for the red blood
cells to clog up the small capillaries. This impedes circulation and ultimately
deprives target organs of blood and oxygen. If matters do not return to normal,
the person can enter a "sickling crisis" in which she/he experiences profound
weakness, pain, and cramps. The medical complications from the anemia and
the slow necrosis (cell death) of the organs lead to early death. Although a
minority of sufferers have a benign course (Thomas et al., 1997), a significant
proportion of people with sickle cell anemia who lack access to modern medicine
do not survive to adulthood (variable expressivity again). Like many lethal
2 There are actually two major alleles, denoted HbS add HbC that can cause the disease.
The HbC allele, however, is rare so most texts focus on HbS.
17
7.6. SICKLE CELL DISEASE
CHAPTER 7. MENDELIAN TRAITS
Figure 7.7: Distribution of the sickle cell allele.
From: http://anthro.palomar.edu/synthetic/synth_4.htm
genetic disorders, however, medical advances have increased both the length
and quality of life of people with sickle cell anemia (Reed and Vichinsky, 1998;
Sheth et al., 2013).
Apart from the medical symptoms, people with sickle cell anemia have normal behavior. They have the same prevalence of psychiatric disorders as members of the general community (Hilton et al., 1997). Intellect and cognitive
functioning are normal, apart from the disruptive and momentary influence of a
sickling crisis and the long term effects of medical complications such as infarcts
(Armstrong et al., 1996). The major lesson from sickle cell anemia resides its
population genetics and not in any behavioral sequelae of the syndrome.
In the past, it was known that the allele for sickle cell anemia was found
in high frequency in areas of Africa, the Saudi Arabian peninsula, and the
Indian subcontinent (see Figure 7.7). Originally, it was speculated that the
mutation for sickle cell anemia originated several thousand years ago among the
Bantu-speaking peoples of Africa and diffused to the other areas, but current
evidence supports the idea that independent mutations occurred in the different
geographical locales (Mears et al., 1981; Solomon and Bodmer, 1979; Wainscoat
et al., 1983). At least four independent mutations occurred in Africa and one in
the Saudi peninsula. Figure 7.8 shows the distribution of the major haplotypes
for the sickle cell allele3 .
After the original mutations, the allele for SCD underwent a unique evolutionary history that corresponded to the presence or absence of a particular form
of malaria (falciparum) in the differing ecologies. It turns out that heterozy3 A haplotype is discussed in Section X.X. Here, it refers to the allele causing sickle cell
disease and other alleles close to it.
18
CHAPTER 7. MENDELIAN TRAITS
7.6. SICKLE CELL DISEASE
Figure 7.8: Distribution of the major sickle cell alleles by origin.
From:
http://www.nature.com/scitable/topicpage/
sickle-cell-anemia-a-look-at-global-8756219
19
7.6. SICKLE CELL DISEASE
CHAPTER 7. MENDELIAN TRAITS
gote carriers (those with one normal and one sickle cell allele) were resistant
to malaria, especially its lethal consequences such as cerebral malaria. In the
heterozygote the red blood cells that carried the malarial parasite would tend
to sickle themselves and be readily destroyed. This prevented the infection from
running amok in a heterozygote and increased the survival rate.
Hence, the frequency of the allele among the various populations evolved
as a function of a malarial ecology. In regions free of malaria, there was no
advantage to the heterozygote, so the sickle cell allele diminished in frequency.
Indeed, the allele is quite rare in many populations of eastern Africa, especially
around the Horn, and southern Africa. In the Saudi peninsula, its prevalence
is high in oasis populations where mosquitoes are encountered but quite rare
among neighboring desert nomads (el Hazmi et al., 1996). In malarial regions,
the allele encountered two opposing selective pressures—the lethality of the
allele in the recessive homozygotes worked to remove it from the population but
the advantage conferred by the allele to the heterozygote worked to increase its
frequency. These two opposing forces eventually arrived at an equilibrium in
which the frequency of the sickle cell allele remained much higher than it did in
nonmalarial areas. To give some figures, the frequency of the sickle cell allele is
.01 or less in some South African populations but exceeds .25 in some areas of
western Africa where malaria could at times reach epidemic proportions.
The major lesson of sickle cell is the complex relationship between genes,
race-ethnicity, and ecology. Somewhere between 5% and 9% of African-Americans
carry the sickle cell allele, and in this country it is often perceived of as a "black"
disorder (Lorey et al., 1996). There is an element of truth to this, but the mere
association of a gene with what we socially define as race and ethnicity is a
gross understatement compared to the rich biology behind sickle cell anemia.
The statistical association that we observe is the visible part of an iceberg fashioned by millennia of environmental adaptation, ecology, evolutionary fitness,
and a big dash of just dumb luck.
The first part of dumb luck is the multiple origins of the mutation. These
origins could have just as well occurred in other malarial regions such as the
Mediterranean or Southeast Asia , but they just happened to occur in Africa and
Saudi Arabia. The second chance event was that the mutation was beneficial
to some—but certainly not all—of the people who carried it. The reason that
it increased in frequency had everything to do with the biology and the ecology
of malaria and absolutely nothing to do with the external morphology that we
use as cues to ethnicity. This is why it spread outside of Africa and from the
Middle East into Asia.
The last piece of dumb luck is the location of the slave trade into the New
World. The majority of embarkation ports were on the West and West-Central
coast of Africa and a majority of victims came from the neighboring indigenous
populations—precisely those areas where malaria occurred in high frequency
and the sickle cell allele was most prevalent. Had the slave trade originated
from ports in South Africa, we would never consider sickle cell anemia as an
"African-American" disease. Had the slave trade originated in some parts of
India instead of western Africa, we might consider it an "Indian-American"
20
CHAPTER 7. MENDELIAN TRAITS
7.6. SICKLE CELL DISEASE
disease.
It is time to reflect once again on the relationship between correlation and
causality—correlations do not necessarily imply causality. The correlation or
the statistical association, if you prefer that term, between sickle cell anemia
and African-American heritage does not imply any direct causality between a
section of DNA coding for hemoglobin and any index of African-Americans.
The causes are dumb luck, evolution, and historical accident.
7.6.1
Discrimination and sickle cell disease
In the 1960s advances in genetic techniques permitted detection of heterozygotes
or carriers of the sickle cell allele. At the same time, many geneticists urged
governments to implement mandatory genetic testing at birth for conditions
like phenylketonuria whose sufferers benefit from early detection and intervention. In the early 1970s, several health-care bills passed by the US earmarked
funds for research into the detection and treatment of SCD along with public
health education about the disorder. Many African-American leaders along with
such diverse groups as the Black Panthers urged African-Americans planning to
marry another African-American to have carrier testing. Such noble intentions,
however, gave way to a distasteful reality.
The first problem was semantic. A heterozygote was said to have “sickle
cell trait,” and there was widespread confusion, even within the medical community between “sickle cell trait” and “sickle cell disease” (Aspinwall, 2012;
Wailoo, 2001). The second problem was the empirical fact that under conditions of oxygen deprivation, including those induced by strenuous exercise,
many people with the disease would undergo a sickling crisis. Coupled with
the semantic confusion, several industries demanded carrier testing for potential African-American applicants and prohibited employment upon a positive
result. For example, the U.S. Air Force and many major airlines prohibited
carriers as pilots or flight attendants (Aspinwall, 2012). The third problem was
overt racism–employers demanded testing to avoid hiring African-Americans.
The consequence was enhanced discrimination against African Americans in
education, insurance, and employment. This reinforced a sense of suspicion in
the African-American community about public health efforts aimed at them. It
took considerable time to overcome the scientific misunderstanding. It wasn’t
until 1981, for example, that the U.S. Air Force Academy ended its policy of
refusing admittance to sickle cell carriers Severo (1981).
It is true that some carriers may suffer adverse health consequences–even
death–but the documented conditions are extreme. Examples include the physical exertion required during basic training in the Armed forces (Kark et al.,
1987) and collegiate football practice (Harmon et al., 2012). The current medical
recommendation is not to screen for sickle cell carriers. Instead, all individuals
undergoing such strenuous activity should be provided with the proper hydration and rest to avoid problems. To put the matter in perspective, the relative
risk for an unexplained death for a sickle cell carrier during basic training was
32 per 100,000. For some aged 26 to 30, however, the relative risk was 95 per
21
7.7. CONCLUSION
CHAPTER 7. MENDELIAN TRAITS
100,000.
7.7
Conclusion
In this chapter we have learned about several mechanisms for disorders. Classic metabolic blocks cause phenylketonuria and congenital adrenal hyperplasia.
In PKU, the deleterious alleles occur at a single locus (that for the enzyme
phenylalanine hydroxylase) while for CAH, the faulty alleles could occur at five
different loci. Errors in genetic regulation can also influence phenotypic irregularity—the abnormal methylation of the FMR-1 locus is responsible for the
Fragile X syndrome.
Genes, however, can act as protective factors that diminish susceptibility
towards disorders. The ALDH-2 polymorphism is a classic example because the
presence of the less frequent allele diminishes the probability of alcohol abuse
and alcohol dependence. This trait also illustrates one biochemical mechanism
for genetic dominance (to be exact—partial dominance). The heterozygote will
produce two types of mRNA that result in two types of translated polypeptide chains—one functional and the other nonfunctional. Because four of these
polypeptide chains must join together to give the ALDH-2 enzyme, only 1 in 16
ALDH-2 molecules in the heterozygote will be functional.
Sickle cell disease illustrates how an allele can be beneficial in one circumstance (i.e., in the heterozygote) but harmful in another (the recessive homozygote). Hence, the influence of an allele or a gene must always be judged against
the genetic background in which it occurs. Sickle cell also demonstrates how
human genetic diversity can be caused by ecological factors giving secondary
correlations with what we socially define as race and ethnicity. For all these
traits, one cannot help but marvel at the degree of penetrance, pleiotropism,
and variable expressivity when the phenotypes are "molar" behaviors such as
cognitive ability, attentional processes, personality, and psychopathology.
It is very likely that the same principles may apply to the genes that underlie more common phenotypes. Perhaps a single gene may have a large effect
on schizophrenia when it occurs along with a certain genetic background but
only a small influence when present in another background. Any particular
locus for, say, intelligence is bound to have considerable variable expressivity.
And the effects of other loci may be to buffer an individual against developing
agoraphobia.
7.8
References
Armstrong, F. D., J., R. J. T., Wang, W., Zimmerman, R., Pegelow, C. H.,
Miller, S., Moser, F., Bello, J., Hurtig, A., and Vass, K. (1996). Cognitive
functioning and brain magnetic resonance imaging in children with sickle cell
disease. neuropsychology committee of the cooperative study of sickle cell
disease. Pediatrics, 97(6):864–870.
22
CHAPTER 7. MENDELIAN TRAITS
7.8. REFERENCES
Aspinwall, T. J. (2012). Imperfect remedies: Legistaltive efforts to prevent
genetic discrimination. Annals of Health Law, 19(1).
Azen, C., Koch, R., Friedman, E., Wenz, E., and Fishler, K. (1996). Summary
of findings from the united states collaborative study of children treated for
phenylketonuria. European journal of pediatrics, 155 Suppl 196426311:S29–32.
Berenbaum, S. A., Bryk, K. L. K., and Beltz, A. M. (2012). Early androgen
effects on spatial and mechanical abilities: Evidence from congenital adrenal
hyperplasia. Behavioral Neuroscience, 126(1):86–96.
Berenbaum, S. A. and Hines, M. (1992b). Early androgens are related to childhood sex-typed toy preferences. Psychological Science, 3(3):203–206.
Berenbaum, S. A. and Resnick, S. M. (1997b). Early androgen effects on aggression in children and adults with congenital adrenal hyperplasia. Psychoneuroendocrinology, 22(7):505–515.
Budimirovic, D. B. and Kaufmann, W. E. (2011). What can we learn about
autism from studying fragile x syndrome?
Developmental neuroscience,
33(5):379–394.
Burgard, P., Schmidt, E., Rupp, A., Schneider, W., and Bremer, H. J. (1996).
Intellectual development of the patients of the german collaborative study
of children treated for phenylketonuria. European journal of pediatrics, 155
Suppl 196426312:S33–8.
Chen, Y. C., Lu, R. B., Peng, G. S., Wang, M. F., Wang, H. K., Ko,
H. C., Chang, Y. C., Lu, J. J., Li, T. K., and Yin, S. J. (1999). Alcohol
metabolism and cardiovascular response in an alcoholic patient homozygous
for the aldh2*2 variant gene allele. Alcoholism, Clinical and Experimental
Research, 23(12):1853–1860.
Cleary, M., Trefz, F., Muntau, A. C., Feillet, F., van Spronsen, F. J., Burlina,
A., Belanger-Quintana, A., Gizewska, M., Gasteyger, C., Bettiol, E., Blau, N.,
and MacDonald, A. (2013). Fluctuations in phenylalanine concentrations in
phenylketonuria: a review of possible relationships with outcomes. Molecular
genetics and metabolism, 110(4):418–423.
Cohen-Bendahan, C. C., van de Beek, C., and Berenbaum, S. A. (2005a). Prenatal sex hormone effects on child and adult sex-typed behavior: methods
and findings. Neuroscience and biobehavioral reviews, 29(2):353–384.
Cohen-Bendahan, C. C. C., van de Beek, C., and Berenbaum, S. A. (2005b).
Prenatal sex hormone effects on child and adult sex-typed behavior: Methods
and findings. Neuroscience and Biobehavioral Reviews, 29(2):353–384.
Diamond, A. (1994). Phenylalanine levels of 6-10 mg/dl may not be as benign
as once thought. Acta Paediatr Suppl, 40795284443:89–91.
23
7.8. REFERENCES
CHAPTER 7. MENDELIAN TRAITS
Diamond, A. (1996). Evidence for the importance of dopamine for prefrontal cortex functions early in life. Philos Trans R Soc Lond B Biol Sci,
351(134697097185):1483–93; discussion 1494.
DiSilvestre, D., Koch, R., and Groffen, J. (1991). Different clinical manifestations of hyperphenylalaninemia in three siblings with identical phenylalanine
hydroxylase genes. American Journal of Human Genetics, 48(5):1014–1016.
Dittmann, R. W., Kappes, M. E., and Kappes, M. H. (1992a). Sexual behavior in adolescent and adult females with congenital adrenal hyperplasia.
Psychoneuroendocrinology, 17(2-3):153–170.
Dittmann, R. W., Kappes, M. H., Kappes, M. E., Borger, D., Meyer-Bahlburg,
H. F., Stegner, H., Willig, R. H., and Wallis, H. (1990b). Congenital adrenal
hyperplasia. ii: Gender-related behavior and attitudes in female salt-wasting
and simple-virilizing patients. Psychoneuroendocrinology, 15(5-6):421–434.
Dittmann, R. W., Kappes, M. H., Kappes, M. E., Borger, D., Stegner, H.,
Willig, R. H., and Wallis, H. (1990c). Congenital adrenal hyperplasia. i:
Gender-related behavior and attitudes in female patients and sisters. Psychoneuroendocrinology, 15(5-6):401–420.
el Hazmi, M., Warsy, A. S., al Swailem, A., al Swailem, A., and Bahakim,
H. M. (1996). Sickle cell gene in the population of saudi arabia. Hemoglobin,
20(397006853):187–198.
Goedde, H. W., Agarwal, D. P., and Harada, S. (1983). Pharmacogenetics of
alcohol sensitivity. Pharmacol Biochem Behav, 18:161–166.
Griffiths, P., Paterson, L., and Harvie, A. (1995). Neuropsychological effect of
subsequent exposure to phenylalanine in adolescents and young adults with
early- treated phenylketonuria. Journal of Intellectual Disability Research,
39:365–372.
Hagerman, R. J. and Hagerman, P. J. (2002). The fragile x premutation:
Into the phenotypic fold. Current Opinion in Genetics and Development,
12(3):273–283.
Harmon, K. G., Drezner, J. A., Klossner, D., and Asif, I. M. (2012). Sickle cell
trait associated with a rr of death of 37 times in national collegiate athletic
association football athletes: a database with 2 million athlete-years as the
denominator. British journal of sports medicine, 46(5):325–330.
Helleday, J., Edman, G., Ritzen, E. M., and Siwers, B. (1993b). Personality
characteristics and platelet mao activity in women with congenital adrenal
hyperplasia (cah). Psychoneuroendocrinology, 18(5-694022767):343–354.
Higuchi, S., Matsushita, S., Muramatsu, T., Murayama, M., and Hayashida, M.
(1996). Alcohol and aldehyde dehydrogenase genotypes and drinking behavior
in japanese. Alcohol Clin Exp Res, 20(396330466):493–497.
24
CHAPTER 7. MENDELIAN TRAITS
7.8. REFERENCES
Hilton, C., Osborn, M., Knight, S., Singhal, A., and Serjeant, G. (1997). Psychiatric complications of homozygous sickle cell disease among young adults
in the jamaican cohort study. Br J Psychiatry, 17097221733:69–76.
Kark, J. A., Posey, D. M., Schumacher, H. R., and Ruehle, C. J. (1987). Sicklecell trait as a risk factor for sudden death in physical training. The New
England journal of medicine, 317(13):781–787.
Koch, R., Hanley, W., Levy, H., Matalon, K., Matalon, R., Rouse, B., Trefz,
F., Guttler, F., Azen, C., Platt, L., Waisbren, S., Widaman, K., Ning, J.,
Friedman, E. G., and de la Cruz, F. (2003b). The maternal phenylketonuria
international study: 1984-2002. Pediatrics, 112(6 Pt 2):1523–1529.
Lorey, F. W., Arnopp, J., and Cunningham, G. C. (1996). Distribution of
hemoglobinopathy variants by ethnicity in a multiethnic state. Genet Epidemiol, 13(597061366):501–512.
Mandel, J. L. and Biancalana, V. (2004). Fragile x mental retardation syndrome:
from pathogenesis to diagnostic issues. Growth hormone & IGF research :
official journal of the Growth Hormone Research Society and the International
IGF Research Society, 14 Suppl A:S158–65.
Martin, J. P. and Bell, J. (1943). A pedigree of mental defect showing sex-link.
Journal of Neurology and Psychiatry, (154-157).
Mears, J. G., Lachman, H. M., Cabannes, R., Amegnizin, K. P., Labie, D., and
Nagel, R. L. (1981). Sickle gene. its origin and diffusion from west africa. J
Clin Invest, 68(382008125):606–610.
Mirchev, R. and Ferrone, F. A. (1997). The structural link between polymerization and sickle cell disease. J Mol Biol, 265(597201131):475–479.
Mitchell, J. J., Trakadis, Y. J., and Scriver, C. R. (2011). Phenylalanine hydroxylase deficiency. Genetics in medicine : official journal of the American
College of Medical Genetics, 13(8):697–707.
Muramatsu, T., Wang, Z. C., Fang, Y. R., Hu, K. B., Yan, H., Yamada, K.,
Higuchi, S., Harada, S., and Kono, H. (1995). Alcohol and aldehyde dehydrogenase genotypes and drinking behavior of chinese living in shanghai. Hum
Genet, 96(295362240):151–154.
Murayama, M., Matsushita, S., Muramatsu, T., and Higuchi, S. (1998). Clinical characteristics and disease course of alcoholics with inactive aldehyde
dehydrogenase-2. Alcohol Clin Exp Res, 22(298240795):524–527.
Nakawatase, T. V., Yamamoto, J., and Sasao, T. (1993). The association between fast-flushing response and alcohol use among japanese americans. J
Stud Alcohol, 54(193360536):48–53.
25
7.8. REFERENCES
CHAPTER 7. MENDELIAN TRAITS
Nelson, D. L., Orr, H. T., and Warren, S. T. (2013). The unstable repeats–three
evolving faces of neurological disease. Neuron, 77(5):825–843.
Peprah, E. (2012). Fragile x syndrome: the fmr1 cgg repeat distribution among
world populations. Annals of Human Genetics, 76(2):178–191.
Reed, W. and Vichinsky, E. P. (1998). New considerations in the treatment of
sickle cell disease. Annu Rev Med, 4998170013:461–474.
Santoro, M. R., Bray, S. M., and Warren, S. T. (2012). Molecular mechanisms
of fragile x syndrome: a twenty-year perspective. Annual review of pathology,
7:219–245.
Scriver, C. R., Hurtubise, M., Konecki, D., Phommarinh, M., Prevost, L.,
Erlandsen, H., Stevens, R., Waters, P. J., Ryan, S., McDonald, D., and
Sarkissian, C. (2003). Pahdb 2003: what a locus-specific knowledgebase can
do. Human mutation, 21(4):333–344.
Seltzer, M. M., Baker, M. W., Hong, J., Maenner, M., Greenberg, J., and
Mandel, D. (2012). Prevalence of cgg expansions of the fmr1 gene in a us
population-based sample. American journal of medical genetics.Part B, Neuropsychiatric genetics : the official publication of the International Society of
Psychiatric Genetics, 159B(5):589–597.
Severo, N. (1981). Air academy to drop its ban on applicants with sickle-cell
gene.
Sherman, S. L., Jacobs, P. A., Morton, N. E., Froster-Iskenius, U., HowardPeebles, P. N., Nielsen, K. B., Partington, M. W., Sutherland, G. R., Turner,
G., and Watson, M. (1985b). Further segregation analysis of the fragile
x syndrome with special reference to transmitting males. Human genetics,
69(4):289–299.
Sherman, S. L., Morton, N. E., Jacobs, P. A., and Turner, G. (1984b). The
marker (x) syndrome: a cytogenetic and genetic analysis. Annals of Human
Genetics, 48(Pt 1):21–37.
Sheth, S., Licursi, M., and Bhatia, M. (2013). Sickle cell disease: time for a
closer look at treatment options? British journal of haematology, 162(4):455–
464.
Solomon, E. and Bodmer, W. F. (1979). Evolution of sickle variant gene. Lancet,
1(812279177121):923.
Steinmetz, C. G., Xie, P., Weiner, H., and Hurley, T. D. (1997). Structure
of mitochondrial aldehyde dehydrogenase: the genetic component of ethanol
aversion. Structure, 5(597341232):701–711.
26
CHAPTER 7. MENDELIAN TRAITS
7.8. REFERENCES
Tanaka, F., Shiratori, Y., Yokosuka, O., Imazeki, F., and e. al (1997). Polymorphism of alcohol-metabolizing genes affects drinking behavior and alcoholic
liver disease in japanese men. Alcoholism: Clinical & Experimental Research,
21:596–601.
Thomas, P. W., Higgs, D. R., and Serjeant, G. R. (1997). Benign clinical course
in homozygous sickle cell disease: a search for predictors. J Clin Epidemiol,
50(297246645):121–126.
Thomasson, H. R., Edenberg, H. J., Crabb, D. W., Mai, X. L., Jerome, R. E., Li,
T. K., Wang, S. P., Lin, Y. T., Lu, R. B., and Yin, S. J. (1991). Alcohol and
aldehyde dehydrogenase genotypes and alcoholism in chinese men. American
Journal of Humam Genetics, 48(491196724):677–681.
Trefz, F., Maillot, F., Motzfeldt, K., and Schwarz, M. (2011). Adult phenylketonuria outcome and management. Molecular genetics and metabolism, 104
Suppl:S26–30.
Trefz, F. K., Burgard, P., Konig, T., Goebel-Schreiner, B., Lichter-Konecki, U.,
Konecki, D., Schmidt, E., Schmidt, H., and Bickel, H. (1993b). Genotypephenotype correlations in phenylketonuria. Clinica chimica acta; international journal of clinical chemistry, 217(1):15–21.
Tu, G. C. and Israel, Y. (1995). Alcohol consumption by orientals in north
america is predicted largely by a single gene. Behavior genetics, 25:59–65.
Turk, J. (2011). Fragile x syndrome: lifespan developmental implications for
those without as well as with intellectual disability. Current opinion in psychiatry, 24(5):387–397.
Wailoo, K. (2001). Dying in the City of Blues: Sickle Cell Anemia and the
Politics of Race and Health. University of North Carolina Press, Chapel Hill,
NC.
Wainscoat, J. S., Bell, J. I., Thein, S. L., Higgs, D. R., Sarjeant, G. R., Peto,
T. E., and Weatherall, D. J. (1983). Multiple origins of the sickle mutation: evidence from beta s globin gene cluster polymorphisms. Mol Biol Med,
1(285060409):191–197.
Wang, T., Bray, S. M., and Warren, S. T. (2012). New perspectives on the
biology of fragile x syndrome. Current opinion in genetics & development,
22(3):256–263.
Yin, S. J. (1994). Alcohol dehydrogenase: enzymology and metabolism. Alcohol
Alcohol Suppl, 297129867:113–119.
Yoshida, A. (1992). Molecular genetics of human aldehyde dehydrogenase. Pharmacogenetics, 2(493306339):139–147.
27
7.8. REFERENCES
CHAPTER 7. MENDELIAN TRAITS
Zucker, K. J., Bradley, S. J., Oliver, G., and Blake, J. (1996a). Psychosexual
development of women with congenital adrenal hyperplasia. Hormones &
Behavior, 30:300–318.
28